For Media: UK Press Releases
This page contains resources intended for journalists only. For media enquiries about our press releases please contact ukmediaenquiries@bayer.com
Darolutamide meets primary endpoint in Phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flushes associated with menopause in women
Bayer's elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
Mirena® (52mg levonorgestrel IUS) authorised in the UK for extended use up to eight years for contraception